Find your next paid study

Dana-Farber Cancer InstituteNCT06940180

~$10 – $7,500

Advanced Non-Small Cell Lung CancerSquamous Cell CarcinomaAdvanced NSCLC+2 more

A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the lab…

National Cancer Institute (NCI)NCT02133196

~$10 – $5,625

Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell Carcinoma+2 more

A Phase 2 Trial of SX-682 and Atezolizumab in Patients With Advanced NSCLC Who Progressed on Prior Chemotherapy and Immune Checkpoint Inhibitor (ICI) Therapy

This phase II trial tests how well SX-682 and atezolizumab works for the treatment of non-small cell lung cancer (NSCLC) that may have spread from where it fir…

University of WashingtonNCT07322341

Phase 1

A Phase I Study of the Intrathecal Administration of Resiniferatoxin for Treating Severe Refractory Pain Associated With Advanced Cancer

This study will examine the safety of giving the experimental drug, resiniferatoxin (RTX), to treat severe pain in patients with advanced cancer. RTX is a chem…

Intractable PainPalliative Care

National Institute of Dental and Craniofacial Research (NIDCR)NCT00804154

~$10 – $5,625

Phase 1

A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia

This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells e…

Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia, RefractoryPediatric ALL

St. Jude Children's Research HospitalNCT04881240

Lung Non-Small Cell CarcinomaMalignant Solid NeoplasmMelanoma+1 more

Phase II Randomized Controlled Trial of Biologically Guided Stereotactic Body Radiation Therapy in Oligoprogressive Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non…

City of Hope Medical CenterNCT05830058

Esophageal CarcinomaGastric Cancer (Diagnosis)Colorectal Adenocarcinoma+3 more

Phase II Basket Trial of Intraperitoneal Paclitaxel Plus Systemic Therapy in Gastrointestinal Malignancies With Peritoneal Carcinomatosis (STOPGAP - B)

This is a phase II open-label, basket clinical trial to assess the feasibility of systemic and Intraperitoneal chemotherapy in subjects with Gastrointestinal M…

University of California, IrvineNCT07795749

Prospective Multiomic Analysis in Small-Cell Lung Cancer to Inform Therapeutic Vulnerabilities and Predict Clinical Outcomes: Deep Phenotyping of Relapsed SCLC Cohort

This is an observational study to collects blood samples and tumor tissue from adults with relapsed small-cell lung cancer (SCLC) receicing standard of care co…

Small Cell Cancer Of The LungSmall Cell Lung Cancer ( SCLC )Lung Cancer+1 more

Ohio State University Comprehensive Cancer CenterNCT07795411

~$10 – $750

Phase 3

A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocyt…

B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Nurix Therapeutics, Inc.NCT07516093

~$10 – $8,750

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

A Phase Two Study of Venetoclax Plus Zanubrutinib in Newly Diagnosed CLL and After Front-Line Time-Limited Venetoclax-Based Therapy

This phase II trial tests the effect of venetoclax in combination with standard of care (SOC) zanubrutinib in treating patients with chronic lymphocytic leukem…

~$10 – $7,500

Kerry RogersNCT07734038

Biliary Tract CancersIntrahepatic Cholangiocarcinoma (Icc)Extrahepatic Cholangiocarcinoma+3 more

A Multi-Institutional Phase 2 Evaluation of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant …

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07793253

Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-…

Relapsed Pediatric ALLHematopoietic Cell TransplantationHematologic Malignancy